A set of serum markers detecting systemic inflammation in psoriatic skin, entheseal, and joint disease in the absence of C-reactive protein and its link to clinical disease manifestations.
Enthesitis
Inflammation
Psoriasis
Psoriatic arthritis
Serum markers
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
12 02 2020
12 02 2020
Historique:
received:
04
11
2019
accepted:
23
01
2020
entrez:
14
2
2020
pubmed:
14
2
2020
medline:
25
11
2020
Statut:
epublish
Résumé
C-reactive protein (CRP) is often normal in patients with psoriatic disease. Herein, we aimed to define markers of systemic inflammation in patients with monomorphic and polymorphic psoriatic skin, entheseal, and joint disease. Three-step approach: (i) selection of serum markers elevated in psoriatic arthritis compared healthy controls from a panel of 10 different markers reflecting the pathophysiology of psoriatic disease; (ii) testing of these selected markers as well as C-reactive protein (CRP) in a larger cohort of 210 individuals- 105 healthy controls and 105 patients with psoriatic disease with either monomorphic skin (S), entheseal (E) or joint (A) involvement or polymorphic disease with various combinations of skin, entheseal and joint disease (SE, SA, EA, SEA); (iii) testing whether tumor necrosis factor (TNF) and interleukin (IL)-17 inhibitor therapy normalizes these markers. CRP was not elevated or was rarely elevated in the subgroups (S 0%, E 0%, A 20%, SE 7%, SA 33%, EA 27%, SEA 33%) despite active psoriatic disease. In sharp contrast, beta-defensin 2 and lipocalin-2 levels were elevated in the majority of patients with monomorphic skin (93% and 73%) and entheseal (both 53%), but not joint disease (27% and 20%). Conversely, elevations of calprotectin and IL-8 were found in the majority of patients with monomorphic joint disease (both 73%). IL-22 was elevated in all three monomorphic disease manifestations (S 60%, E 46%; A 60%). Furthermore, the vast majority of patients with polymorphic psoriatic disease (SE, SA, EA, SEA) showed widespread marker elevation. IL-17- and TNF inhibitor treatment significantly lowered all 5 markers of inflammation in PsA patients. Systemic inflammation is detectable in the majority of patients with psoriatic disease, even if CRP is normal. The respective marker pattern depends on the manifestation of psoriatic disease with respect to skin, entheseal, and joint involvement.
Sections du résumé
BACKGROUND
C-reactive protein (CRP) is often normal in patients with psoriatic disease. Herein, we aimed to define markers of systemic inflammation in patients with monomorphic and polymorphic psoriatic skin, entheseal, and joint disease.
METHODS
Three-step approach: (i) selection of serum markers elevated in psoriatic arthritis compared healthy controls from a panel of 10 different markers reflecting the pathophysiology of psoriatic disease; (ii) testing of these selected markers as well as C-reactive protein (CRP) in a larger cohort of 210 individuals- 105 healthy controls and 105 patients with psoriatic disease with either monomorphic skin (S), entheseal (E) or joint (A) involvement or polymorphic disease with various combinations of skin, entheseal and joint disease (SE, SA, EA, SEA); (iii) testing whether tumor necrosis factor (TNF) and interleukin (IL)-17 inhibitor therapy normalizes these markers.
RESULTS
CRP was not elevated or was rarely elevated in the subgroups (S 0%, E 0%, A 20%, SE 7%, SA 33%, EA 27%, SEA 33%) despite active psoriatic disease. In sharp contrast, beta-defensin 2 and lipocalin-2 levels were elevated in the majority of patients with monomorphic skin (93% and 73%) and entheseal (both 53%), but not joint disease (27% and 20%). Conversely, elevations of calprotectin and IL-8 were found in the majority of patients with monomorphic joint disease (both 73%). IL-22 was elevated in all three monomorphic disease manifestations (S 60%, E 46%; A 60%). Furthermore, the vast majority of patients with polymorphic psoriatic disease (SE, SA, EA, SEA) showed widespread marker elevation. IL-17- and TNF inhibitor treatment significantly lowered all 5 markers of inflammation in PsA patients.
CONCLUSIONS
Systemic inflammation is detectable in the majority of patients with psoriatic disease, even if CRP is normal. The respective marker pattern depends on the manifestation of psoriatic disease with respect to skin, entheseal, and joint involvement.
Identifiants
pubmed: 32051028
doi: 10.1186/s13075-020-2111-8
pii: 10.1186/s13075-020-2111-8
pmc: PMC7017480
doi:
Substances chimiques
Biomarkers
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
26Références
J Allergy Clin Immunol. 2017 Mar;139(3):923-932.e8
pubmed: 27502297
J Rheumatol. 2012 Feb;39(2):423-6
pubmed: 22298272
N Engl J Med. 2017 May 25;376(21):2095-6
pubmed: 28538114
J Immunol Res. 2014;2014:696415
pubmed: 24955375
Ann Rheum Dis. 2013 Apr;72 Suppl 2:ii104-10
pubmed: 23532439
J Immunol Res. 2014;2014:467541
pubmed: 25759829
AAPS J. 2017 Jul;19(4):1218-1222
pubmed: 28534291
Osteoarthritis Cartilage. 2019 Jul;27(7):1043-1047
pubmed: 30890457
J Dermatol. 2013 Oct;40(10):805-12
pubmed: 23915382
Arthritis Res Ther. 2010;12(4):R148
pubmed: 20642840
J Rheumatol. 2013 Jun;40(6):866-71
pubmed: 23637322
Indian Dermatol Online J. 2015 Sep-Oct;6(5):322-5
pubmed: 26500861
J Dermatol. 2011 May;38(5):442-6
pubmed: 21352285
Sci Transl Med. 2016 Mar 16;8(330):330ra37
pubmed: 27089206
Arch Dermatol Res. 2013 Mar;305(2):105-12
pubmed: 23242471
J Dermatol Sci. 2010 Jun;58(3):225-7
pubmed: 20418068
Arthritis Rheumatol. 2019 Oct;71(10):1660-1669
pubmed: 31070869
Arthritis Rheumatol. 2014 Dec;66(12):3300-10
pubmed: 25155522
Mediators Inflamm. 2005 Oct 24;2005(5):273-9
pubmed: 16258194
Ann Rheum Dis. 2019 Jun;78(6):796-801
pubmed: 30910989
Arthritis Rheumatol. 2016 Sep;68(9):2163-73
pubmed: 27059799
Rheumatology (Oxford). 2010 Jul;49(7):1399-405
pubmed: 20421218
Int J Mol Med. 2006 Sep;18(3):415-23
pubmed: 16865225
J Rheumatol. 2013 Aug;40(8):1453-4
pubmed: 23908545
Mediators Inflamm. 2014;2014:268257
pubmed: 25197165
Dis Markers. 2013;35(6):625-31
pubmed: 24288431